

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

NCT06941389

Status	RECRUITING
Sponsor	University of Rochester
Enrollment	480 participants

Key Eligibility Criteria

Inclusion (6)

- Pediatric patients aged between 3 and 20.9 years.
- Children diagnosed with sickle cell Anemia (HB SS or HBSB0 Thalassemia)
- For the MRD HCT group, children who are candidates for matched related donor hematopoietic stem cell transplantation (MRD HCT).
- For the NT-DMT group, children who are receiving non-transplant disease-modifying therapies (NT-DMT) for SCD.
- Participants (or their guardians) must provide informed consent to be part of the study.
- ... and 1 more (see full listing online)

Exclusion (5)

- Children younger than 3 years or older than 20.9 years.
- Children who do not have sickle cell anemia or related conditions.
- For the MRD HCT group, children who are not eligible for the transplant or do not have a matched related donor.
- Children who are currently enrolled in other clinical trials that might interfere with the WeDecide study.
- Children who are unable to adhere to the study protocol or follow-up requirements.

Locations (37 total)

Children's of Alabama (MRD-HCT), Birmingham, Alabama, United States
Children's of Alabama (NT-DMT), Birmingham, Alabama, United States
Nemours Children's Hospital, Delaware (MRD-HCT), Wilmington, Delaware, United States
... and 34 more locations